Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature Visser M; Paulus WJ; Vermeulen MA; Richir MC; Davids M; Wisselink W; de Mol BA; van Leeuwen PAEur J Heart Fail 2010[Dec]; 12 (12): 1274-81Nitric oxide (NO) is formed from arginine by the enzyme nitric oxide synthase (NOS). Asymmetric dimethylarginine (ADMA) can inhibit NO production by competing with arginine for NOS binding. Therefore, the net amount of NO might be indicated by the arginine/ADMA ratio. In turn, arginine can be metabolized by the enzyme arginase, and ADMA by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). While ADMA has been implicated as a cardiovascular risk factor, arginine supplementation has been indicated as a treatment in cardiac diseases. This review discusses the roles of ADMA and arginine in the failing heart and its vasculature. Furthermore, it proposes nutritional therapies to improve NO availability.|Amidohydrolases/*metabolism[MESH]|Arginine/*analogs & derivatives/metabolism/pharmacology[MESH]|Citrulline/therapeutic use[MESH]|Coronary Vessels/drug effects/metabolism[MESH]|Glutamic Acid/therapeutic use[MESH]|Heart Failure/diet therapy/*enzymology/metabolism[MESH]|Humans[MESH]|Nitric Oxide/*metabolism[MESH]|Reactive Oxygen Species[MESH] |